- July 9, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Cesamet
Synonyms :
nabilone
Class :
Antiemetic agents
Dosage forms & Strengths
Schedule II Capsule
1mg
chemotherapy Induced Vomiting and Nausea
1 to 2 mg of nabilone, orally every 8 to 12 hours, is indicated for nausea/vomiting induced after chemotherapy
Not more than 6 mg per day should be administered
Renal impairment
No dose adjustment is required
chemotherapy Induced Vomiting and Nausea
For nausea/vomiting due to chemotherapy in pediatric patients, more than 4 years
Less than 18 kg of body weight: 0.5 mg orally every 12 hours
18-30 kg of body weight: 1 mg orally every 12 hours
More than 30 kg of body weight: 1 mg orally every 8 hours
Dosage forms & Strengths
Schedule II Capsule
1mg
Dosage forms & Strengths
Schedule II Capsule
1mg
chemotherapy Induced Vomiting and Nausea
1-2 mg orally every 8-12 hours
Do not exceed the dose of more than 6 mg every 8 hours
may have an increased effect of a CNS depressant when combined with cannabinoid products
may have an increased effect of a CNS depressant when combined with cannabinoid products
may have an increased effect of a CNS depressant when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
when used in combination, nabilone and sodium oxybate both increase the effect of each other
when used in combination, nabilone and metoclopramide both increase the effect of each other
when used in combination, nabilone and calcium/magnesium oxybate both increase the effect of each other
CNS depressants increase the efficacy of cannabinoid products
CNS depressants increase the efficacy of cannabinoid products
CNS depressants increase the efficacy of cannabinoid products
nabilone and alprazolam, when used simultaneously, both increase the sedation
nabilone and baclofen, when used simultaneously, both increase the sedation
nabilone and loxapine, when used simultaneously, both increase the sedation
nabilone and oxazepam, when used simultaneously, both increase the sedation
nabilone and risperidone, when used simultaneously, both increase the sedation
nabilone and triprolidine, when used simultaneously, both increase the sedation
nabilone and ziprasidone, when used simultaneously, both increase the sedation
may enhance the tachycardiac effect
may enhance the tachycardiac effect
may enhance the tachycardiac effect
may enhance the tachycardiac effect
may enhance the tachycardiac effect
may enhance the CNS depressant effect of cannabinoid-containing products
may enhance the CNS depressant effect of cannabinoid-containing products
may enhance the CNS depressant effect of cannabinoid-containing products
may enhance the CNS depressant effect of cannabinoid-containing products
may enhance the CNS depressant effect of cannabinoid-containing products
CNS depressants increase the efficacy of cannabinoid-containing products
CNS depressants increase the efficacy of cannabinoid-containing products
CNS depressants increase the efficacy of cannabinoid-containing products
May have an increased serotonergic effect when combined with Serotonergic Agents
may have an increased CNS depressant effect when combined with cannabinoid-containing products
may have an increased CNS depressant effect when combined with cannabinoid-containing products
may have an increased CNS depressant effect when combined with cannabinoid-containing products
may have an increased tachycardic effect when combined with sympathomimetics
may have an increased tachycardic effect when combined with sympathomimetics
may have an increased tachycardic effect when combined with sympathomimetics
may have an increased tachycardic effect when combined with sympathomimetics
may have an increased tachycardic effect when combined with sympathomimetics
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
may decrease the serum concentration when combined with CYP1A2 substrates
may decrease the serum concentration when combined with CYP1A2 substrates
may decrease the serum concentration when combined with CYP1A2 substrates
may decrease the serum concentration when combined with CYP1A2 substrates
may decrease the serum concentration when combined with CYP1A2 substrates
anticholinergic agents increase the effect of cannabinoid products
anticholinergic agents increase the effect of cannabinoid products
anticholinergic agents increase the effect of cannabinoid products
anticholinergic agents increase the effect of cannabinoid products
anticholinergic agents increase the effect of cannabinoid products
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of CNS depressants
may increase the tachycardiac effect of sympathomimetics
may have an increased CNS depressive effect when combined with cannabinoid-containing products
may have an increased CNS depressive effect when combined with cannabinoid-containing products
may have an increased CNS depressive effect when combined with cannabinoid-containing products
may increase the toxic effect of CNS muscle relaxants
